Old Web
English
Sign In
Acemap
>
authorDetail
>
Wei Liang
Wei Liang
AstraZeneca
Bendamustine
Rituximab
Acalabrutinib
Medicine
Internal medicine
2
Papers
88
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2020
Journal of Clinical Oncology
Paolo Ghia
Andrzej Pluta
Malgorzata Wach
Daniel Lysák
Tomas Kozak
Martin Simkovic
Polina Kaplan
Iryna Kraychok
Árpád Illés
Javier de la Serna
Sean Dolan
Phillip Campbell
Gerardo Musuraca
Abraham Jacob
Eric Joseph Avery
Jae Hoon Lee
Wei Liang
Priti Patel
Cheng Quah
Wojciech Jurczak
Show All
Source
Cite
Save
Citations (87)
Acalabrutinib versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL: The Randomised, Controlled, Phase 3 ASCEND Trial
2019
Paolo Ghia
Andrzej Pluta
Malgorzata Wach
Daniel Lysák
Tomas Kozak
Martin Simkovic
Polina Kaplan
Iryna Kryachok
Árpád Illés
Javier de la Serna
Sean Dolan
Phillip Campbell
Gerardo Musuraca
Abraham Jacob
Eric J. Avery
Jae Hoon Lee
Wei Liang
Priti Patel
Cheng Quah
Wojciech Jurczak
Show All
Source
Cite
Save
Citations (1)
1